Identification of Drug Combinations Containing Imatinib for Treatment of BCR-ABL+ Leukemias

PLoS ONE - United States
doi 10.1371/journal.pone.0102221
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

A Non-Atp-Competitive Inhibitor of BCR-ABL Overrides Imatinib Resistance

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2005English

In Vivo Imaging of BCR-Abl Overexpressing Tumors With a Radiolabeled Imatinib Analog as an Imaging Surrogate for Imatinib

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2011English

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research
Cancer ResearchOncology
2004English

NPB001-05 Inhibits BCR-Abl Kinase Leading to Apoptosis of Imatinib-Resistant Cells

Frontiers in Bioscience - Elite
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2011English

ON012380: A Non-Atp Competitive Inhibitor of BCR-ABL for the Therapy of Imatinib-Resistant CMLs

2009English

Semi‑random Mutagenesis Profile of BCR‑ABL During Imatinib Resistance Acquirement in K562 Cells

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2017English

Simultaneous Targeting of Aurora Kinases and BCR-Abl Kinase by the Small Molecule Inhibitor PHA-739358 Is Effective Against Imatinib-Resistant BCR-ABL Mutations Including T315I

Blood
BiochemistryImmunologyCell BiologyHematology
2008English

Coexistence of AML1/RUNX1 and BCR-ABL Point Mutations in an Imatinib-Resistant Form of CML

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

In Vitro and in Vivo Activity of SKI-606, a Novel SRC-Abl Inhibitor, Against Imatinib-Resistant BCR-Abl+ Neoplastic Cells

Cancer Research
Cancer ResearchOncology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy